ORIC Pharmaceuticals, Inc.
Financials
Valuation Metrics
ORIC Pharmaceuticals, Inc.'s Market Cap is $938M. At end of 2025 it was $718M. Ranked #2464 of 3,116 in US market (top 79%), #1014 of 1,472 on NASDAQ (top 69%), #185 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 70%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $938M | US#2,464/3,116 Sec#185/265 |
| Revenue | $0.00 | US#2,859/3,116 Sec#193/265 |
| Net Income | $-140M | US—/3,116 Sec—/265 |
| Total Assets | $405M | US#2,831/3,116 Sec#183/265 |
| Net Assets | $381M | US#2,386/3,116 Sec#138/265 |
| Employees | 111 | US#2,591/3,116 Sec#168/265 |
| Value | ||
| P/B | 2.46x | US#1,508/3,116 Sec#75/265 |
| FCF Yield | -11.99% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | -36.81% | US#2,600/3,116 Sec#126/265 |
| ROA | -34.68% | US#2,911/3,116 Sec#172/265 |
| Financial Health | ||
| Debt Ratio | 6.15% | US#52/3,116 Sec#23/265 |
| Total Debt | $3M | US#2,923/3,116 Sec#225/265 |
| FCF | $-112M | US#2,656/3,116 Sec#155/265 |
| Cash | $37M | US#2,684/3,116 Sec#238/265 |
| Current Ratio | 13.19x | US#185/3,116 Sec#57/265 |
| Performance | ||
| 1Y Return | -31.16% | US#2,617/3,116 Sec#212/265 |
| 1M Return | -25.80% | US#3,039/3,116 Sec#252/265 |
| From 52W High | -38.28% | US#2,350/3,116 Sec#168/265 |
| 1Y MDD | -46.11% | US#2,222/3,116 Sec#146/265 |
| Trading | ||
| Volume | 1,002,484 shares | US#1,467/3,116 Sec#147/265 |
| Trading Value | $9M | US#2,324/3,116 Sec#184/265 |
| Per Share | ||
| EPS | $-1.36 | US—/3,116 Sec—/265 |
| BPS | $3.68 | US#2,392/3,116 Sec#145/265 |
Company Info
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.